Virtual Screening and Scaffold Hopping Based on GRID Molecular Interaction Fields
暂无分享,去创建一个
Ismael Zamora | Marie M. Ahlström | Marianne Ridderström | Kristina Luthman | K. Luthman | I. Zamora | M. Ridderström
[1] Gavin Harper,et al. Drug rings database with web interface. A tool for identifying alternative chemical rings in lead discovery programs. , 2003, Journal of medicinal chemistry.
[2] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[3] B. Katz,et al. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. , 2000, Chemistry & biology.
[4] P J Thomas,et al. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template. , 1999, Biochemistry.
[5] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[6] C. Supuran,et al. Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1. , 2000, Journal of medicinal chemistry.
[7] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[8] J. Janc,et al. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. , 2002, Journal of molecular biology.
[9] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[10] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[11] G. S. Gill,et al. Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT) , 2004 .
[12] A. Carroll,et al. Dysinosin A: a novel inhibitor of Factor VIIa and thrombin from a new genus and species of Australian sponge of the family Dysideidae. , 2002, Journal of the American Chemical Society.
[13] Thomas A. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[14] J. Jenkins,et al. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. , 2004, Journal of medicinal chemistry.
[15] Lydia Tabernero,et al. Crystallographic determination of the structures of human α‐thrombin complexed with BMS‐186282 and BMS‐189090 , 1996, Protein science : a publication of the Protein Society.
[16] D. Royston,et al. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. , 2002, British journal of anaesthesia.
[17] David Weininger,et al. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..
[18] C. Derian,et al. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates. , 2001, Journal of medicinal chemistry.
[19] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[20] W. Bode,et al. Complex structure of human thrombin with N-methyl-arginine inhibitor , 2002 .
[21] Gabriele Cruciani,et al. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.
[22] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[23] P. Weber,et al. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine, and ornithine analogs. , 1995, Biochemistry.
[24] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[25] Daniel R McMasters,et al. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. , 2003, Journal of medicinal chemistry.
[26] Schmid,et al. "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.
[27] R. Wade,et al. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. , 1989, Journal of medicinal chemistry.
[28] J H Matthews,et al. Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin. , 1999, Journal of medicinal chemistry.
[29] J. Spurlino,et al. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes. , 1998, Journal of medicinal chemistry.
[30] R. Huber,et al. The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989, The EMBO journal.
[31] J. Valverde. Molecular Modelling: Principles and Applications , 2001 .
[32] Philip M Dean,et al. Scaffold hopping in de novo design. Ligand generation in the absence of receptor information. , 2004, Journal of medicinal chemistry.
[33] H. Nar,et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. , 2002, Journal of medicinal chemistry.
[34] J H Matthews,et al. Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site. , 1996, Biophysical journal.
[35] Ramon Carbo,et al. How similar is a molecule to another? An electron density measure of similarity between two molecular structures , 1980 .
[36] Robert J. Jilek,et al. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.
[37] Lars Naerum,et al. Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[38] J. Maraganore,et al. Thrombin structure and function: why thrombin is the primary target for antithrombotics. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[39] D. Nöteberg,et al. New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography. , 2000, Journal of medicinal chemistry.
[40] Thierry Langer,et al. Pharmacophore Identification, in Silico Screening, and Virtual Library Design for Inhibitors of the Human Factor Xa , 2005, J. Chem. Inf. Model..
[41] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[42] R. Dolle. Comprehensive survey of combinatorial library synthesis: 2000. , 2001, Journal of combinatorial chemistry.
[43] H. Bertrand,et al. Structure-based virtual screening: an application to human topoisomerase II alpha. , 2004, Journal of medicinal chemistry.
[44] Miklos Feher,et al. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. , 2003, Journal of medicinal chemistry.
[45] S Wold,et al. Multivariate data analysis and experimental design in biomedical research. , 1988, Progress in medicinal chemistry.
[46] G. S. Gill,et al. Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT) , 2004, 2004 IEEE International Conference on Systems, Man and Cybernetics (IEEE Cat. No.04CH37583).
[47] W L Jorgensen,et al. Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations. , 2001, Journal of medicinal chemistry.
[48] A. Tulinsky,et al. Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding. , 1999, Acta crystallographica. Section D, Biological crystallography.
[49] M. Zhang,et al. The crystal structures of human α‐thrombin complexed with active site‐directed diamino benzo[b] thiophene derivatives: A binding mode for a structurally novel class of inhibitors , 2008, Protein science : a publication of the Protein Society.
[50] Y. Konishi,et al. Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1', P2', and P3' substrate residues. , 1996, Biochemistry.
[51] K. Fukasawa,et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. , 2001, Journal of medicinal chemistry.
[52] S Wold,et al. Statistical molecular design, parallel synthesis, and biological evaluation of a library of thrombin inhibitors. , 2001, Journal of medicinal chemistry.
[53] R. Dolle. Comprehensive survey of combinatorial library synthesis: 2001. , 2002, Journal of combinatorial chemistry.
[54] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[55] Luc Morin-Allory,et al. Optimization and validation of a docking-scoring protocol; application to virtual screening for COX-2 inhibitors. , 2005, Journal of medicinal chemistry.
[56] Y. Martin,et al. 3D database searching in drug design. , 1992, Journal of medicinal chemistry.
[57] M. Bolognesi,et al. Human alpha-thrombin inhibition by the highly selective compounds N-ethoxycarbonyl-D-Phe-Pro-alpha-azaLys p-nitrophenyl ester and N-carbobenzoxy-Pro-alpha-azaLys p-nitrophenyl ester: a kinetic, thermodynamic and X-ray crystallographic study. , 1997, Journal of molecular biology.
[58] Robert Bywater,et al. Improving the Odds in Discriminating "Drug-like" from "Non Drug-like" Compounds , 2000, J. Chem. Inf. Comput. Sci..
[59] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[60] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[61] D. R. Holland,et al. Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl- piperidin-3-yl)-propanoic acid at P1. , 2000, Journal of medicinal chemistry.
[62] Dawoon Jung,et al. Virtual docking approaches to protein kinase B inhibition. , 2005, Journal of medicinal chemistry.
[63] Rémy D. Hoffmann,et al. Structure-Based Virtual Screening: An Application to Human Topoisomerase II α , 2004 .